Pharmaceutical Stocks To Follow Now - August 18th

Key Points

• Five pharmaceutical stocks to watch include Eli Lilly, Novo Nordisk, Soligenix, AbbVie, and Pfizer, all of which have exhibited high trading volumes in recent days.
• Eli Lilly's stock is currently down 14% post-earnings, hitting $697.94, despite having a strong market cap of $660.57 billion and a P/E ratio of 45.55.
• Novo Nordisk's shares rose to $54.04 during trading, as the company focuses on diabetes and obesity care, highlighting its robust market presence with a significant $241.31 billion market cap.

Eli Lilly and Company, Novo Nordisk A/S, Soligenix, AbbVie, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies engaged in the research, development, manufacturing and marketing of prescription drugs, vaccines and other therapeutic products. Their performance is driven by factors such as regulatory approvals, patent lifecycles, clinical trial results and R&D pipelines, making them potentially volatile but also a key component of many diversified healthcare investment portfolios. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

LLY stock traded down $3.30 during midday trading on Monday, hitting $697.94. 3,062,703 shares of the stock traded hands, compared to its average volume of 4,155,857. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock's fifty day simple moving average is $764.55 and its 200-day simple moving average is $794.43. The firm has a market cap of $660.57 billion, a P/E ratio of 45.55, a PEG ratio of 0.98 and a beta of 0.44.

Read Our Latest Research Report on LLY

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Shares of NYSE:NVO traded up $2.21 during trading on Monday, reaching $54.04. 25,402,453 shares of the company's stock traded hands, compared to its average volume of 11,552,555. The firm has a market cap of $241.31 billion, a PE ratio of 14.84, a P/E/G ratio of 1.80 and a beta of 0.63. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $139.74. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a 50-day simple moving average of $64.96 and a 200-day simple moving average of $70.24.

Read Our Latest Research Report on NVO

Soligenix (SNGX)

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.

Shares of SNGX stock traded up $2.67 during trading hours on Monday, hitting $5.45. 161,259,422 shares of the company's stock were exchanged, compared to its average volume of 4,334,955. Soligenix has a fifty-two week low of $1.09 and a fifty-two week high of $6.23. The firm has a market cap of $17.77 million, a P/E ratio of -1.43 and a beta of 1.95. The firm has a 50 day moving average of $1.79 and a two-hundred day moving average of $2.01.

Read Our Latest Research Report on SNGX

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV stock traded down $0.15 on Monday, reaching $206.54. 3,280,877 shares of the company were exchanged, compared to its average volume of 6,687,899. AbbVie has a 1 year low of $163.81 and a 1 year high of $218.66. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The business has a 50-day moving average price of $191.08 and a 200 day moving average price of $192.31. The company has a market cap of $364.87 billion, a price-to-earnings ratio of 98.36, a P/E/G ratio of 1.33 and a beta of 0.50.

Read Our Latest Research Report on ABBV

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Shares of NYSE PFE traded up $0.01 during midday trading on Monday, hitting $25.15. The stock had a trading volume of 22,444,637 shares, compared to its average volume of 45,501,457. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a 50 day simple moving average of $24.60 and a 200-day simple moving average of $24.42. The company has a market capitalization of $142.96 billion, a PE ratio of 13.36, a P/E/G ratio of 0.89 and a beta of 0.52. Pfizer has a 1 year low of $20.92 and a 1 year high of $30.43.

Read Our Latest Research Report on PFE

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.